Monopar Therapeutics director sells 8,400 shares
The reported transactions were made under a Rule 10b5-1 Plan executed on May 28, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) director Christopher M. Starr exercised stock options for 8,400 common shares at $0.005 per share on October 1, 2026, and sold 8,400 shares in three transactions: 4,631 at a weighted average price of $78.09, 2,970 at $78.82, and 799 at $79.67. The respective sale prices ranged from $77.50 to $78.49, $78.50 to $79.49, and $79.50 to $80.01, inclusive. The transactions were effected pursuant to a Rule 10b5-1 Plan executed May 28, 2026. The reported positions following the transactions include 8,400 stock options and 9,880 common shares held by the Christopher M. Starr and Sheri L. Starr Revocable Trust, for which Starr serves as trustee.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,400 shares ($659K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
STARR CHRISTOPHER M
Role
Director
Sold
8,400 shs ($659K)
Approx. gross sale proceeds
$659K
Approx. exercise cost
$42.00
Approx. pre-tax spread
$659K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F2 | 8,400 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 8,400 | $0.005 | $42.00 |
| Sale | Common Stock F1, F4 | 4,631 | $78.09 | $362K |
| Sale | Common Stock F1, F5 | 2,970 | $78.82 | $234K |
| Sale | Common Stock F1, F6 | 799 | $79.67 | $64K |
| holding | Common Stock F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 8,400 contracts (Direct);
Common Stock — 5,173 shares (Direct);
Common Stock — 9,880 shares (Indirect, See Footnote)
Footnotes (6)
- F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.
- F2. On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.
- F3. Represents shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Key Figures
Shares acquired through option exercise: 8,400 shares
Exercise price: $0.005 per share
First sale transaction: 4,631 shares at a weighted average price of $78.09 per share
+4 more
7 metrics
Shares acquired through option exercise
8,400 shares
October 1, 2026
Exercise price
$0.005 per share
Stock options exercised October 1, 2026
First sale transaction
4,631 shares at a weighted average price of $78.09 per share
Prices ranged from $77.50 to $78.49, inclusive; October 1, 2026
Second sale transaction
2,970 shares at a weighted average price of $78.82 per share
Prices ranged from $78.50 to $79.49, inclusive; October 1, 2026
Third sale transaction
799 shares at a weighted average price of $79.67 per share
Prices ranged from $79.50 to $80.01, inclusive; October 1, 2026
Stock options following transaction
8,400 options
Exercise price $0.005 per share; expiration February 19, 2027
Revocable Trust common shares
9,880 shares
Held by the Christopher M. Starr and Sheri L. Starr Revocable Trust
Key Terms
Rule 10b5-1 Plan, weighted average price, stock options
3 terms
Rule 10b5-1 Plan regulatory
"effected pursuant to a Rule 10b5-1 Plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"the reporting person was granted stock options to purchase"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many MNPR stock options did Christopher M. Starr report after the exercise?
The reported position following the transaction was 8,400 stock options, with an exercise price of $0.005 per share and an expiration date of February 19, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
